ACXPAcurx Pharmaceuticals Inc
ACXP
Acurx Pharmaceuticals Inc2,109
Mkt Cap
$7.93MVolume
80,368.0052W High
$21.0052W Low
$1.33PE Ratio
-0.36ACXP Fundamentals
Price
$2.16Prev Close
$2.16Open
$2.2850D MA
$2.99Beta
1.06Avg. Volume
175,478.00EPS (Annual)
-$5.32P/B
0.96Rev/Employee
$0.00$3.82
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase PR Newswire STATEN ISLAND, N.Y., April 29, 2026 STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire...
PR Newswire·3d ago
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results...
PR Newswire·12d ago
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire STATEN ISLAND...
PR Newswire·16d ago
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct...
PR Newswire·16d ago
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Zacks·30d ago
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR...
PR Newswire·1mo ago
Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·1mo ago
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Zacks·2mo ago
AI, Diagnostics and Next-Gen Materials Drive Innovation Push Across Emerging Growth Stocks
A wave of developments across emerging technology and life sciences companies underscores how artificial intelligence, advanced diagnostics, and next-generation biomaterials are converging to reshape several high-growth sectors. $ISPC, $AIFF, $KBLB, $BIAF, $ACXP, $KIDZ
24-7 Market News·2mo ago
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business...
PR Newswire·2mo ago
<
1
2
...
>